Sign in
TerminatedPhase 1/2

Biological Response to Platelet-rich Plasma and Corticosteroid Injections

Key facts

Who runs it
University of Missouri-Columbia
Where
Columbia, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 1/2
People taking part
23 people enrolled
Started
28 Dec 2022
Ended
18 Jun 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Triamcinolone Acetonide 40 mg/ml Inj, Susp
  • Platelet-rich plasma Inj
Record updated
25 June 2025
Why it stopped
Principal Investigator is Retiring.

Who can take part

Age
40 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Patients aged 40 and over, presenting with a knee disorder of at least one knee
  • Patients eligible for use of either corticosteroid or biological agent for treatment of moderate or severe (but not end-stage) knee osteoarthritis
  • KL grade of 2-3

Who cannot take part

  • Previous reconstructive knee surgery
  • Unable to receive corticosteroid injections (i.e., allergies, adverse reactions, etc.)
  • Subjects less than 40 years of age
  • Participating in another clinical trial
  • Unable to sign informed consent
  • Pregnant or plan to become pregnant

Where in United States

  • University of MissouriColumbia, United States

About the trial

What the trial wants to find out

The goal is to determine how two different injections, corticosteroid and platelet-rich plasma, are used to treat patients with knee osteoarthritis may affect a patient's pain and function. Secondarily, the investigators are also interested in knowing how the two types of injections that will be given may affect what happens in the joint cartilage. The participants will receive one of the two injection types at the initial visit. There will be surveys to complete (around 10 questions) about the participants' knee and overall function. The investigators will ask these same questions on seven separate occasions. In addition, the investigators will ask the participants to provide blood and urine samples at our clinic before the first knee injection and before any other injection that is needed over the course of the study. During the injections, synovial fluid will be aspirated from the participants' knee at the initial visit and the one month visit. If the participants decide to go to surgery to help relieve the pain from osteoarthritis at any point during the study, the investigators will collect the material from the participants' knee that would be normally discarded as medical waste.

Read full original descriptionShow less

Previous studies have indicated that concentrations of inflammatory and degradative biomarkers in patient serum, urine, and synovial fluid may provide insight into OA pathophysiology. To our knowledge, no study has been performed to assess the impact of intra-articular PRP injection upon fluid concentrations of a comprehensive panel of proposed OA-related biomarkers. In this study, the investigators will evaluate the impact of intra-articular PRP injection upon markers of cartilage matrix turnover, inflammatory mediators, degradative enzymes, inhibitors of degradative enzymes, and markers of bone metabolism in serum, urine, and synovial fluid of knee OA patients.

The 2 groups in the trial

  • SteroidExisting treatment, for comparison

    A 6mL injection at the initial visit of triamcinolone 40 mg/1 mL (Kenalog) with 5 mL of 1% lidocaine

    Treatment: Triamcinolone Acetonide 40 mg/ml Inj, Susp

  • Platelet-rich PlasmaTreatment being tested

    An injection at the initial visit of approximately 4-6 mL of PRP

    Treatment: Platelet-rich plasma Inj

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
25 June 2025